Effects of cinacalcet on magnesium and potassium metabolism in peritoneal dialysis patients with residual renal function

DOI Web Site 36 References Open Access
  • Shibata Kanako
    College of Pharmacy, Kinjo Gakuin University
  • Ito Yasuhiko
    Department of Nephrology, Nagoya University Graduate School of Medicine
  • Mizuno Masashi
    Department of Nephrology, Nagoya University Graduate School of Medicine
  • Suzuki Yasuhiro
    Department of Nephrology, Nagoya University Graduate School of Medicine
  • Hiramatsu Hideki
    Department of Nephrology, Nagoya University Graduate School of Medicine
  • Ito Isao
    Department of Nephrology, Nagoya University Graduate School of Medicine
  • Toda Susumu
    Department of Nephrology, Nagoya University Graduate School of Medicine
  • Maruyama Shoichi
    Department of Nephrology, Nagoya University Graduate School of Medicine
  • Matsuo Seiichi
    Department of Nephrology, Nagoya University Graduate School of Medicine

Bibliographic Information

Other Title
  • 残腎機能を有する腹膜透析患者に対するシナカルセト投与時のＭｇ，Ｋ代謝に及ぼす影響
  • ザンジンキノウ オ ユウスル フクマク トウセキ カンジャ ニ タイスル シナカルセト トウヨジ ノ Mg K タイシャ ニ オヨボス エイキョウ

Search this article

Description

Cinacalcet, a calcimimetic agent, binds to the calcium-sensing receptor (CaSR) and effectively decreases parathyroid hormone (PTH) secretion. CaSR is expressed in organs such as the parathyroid, kidneys, and bone. In the kidneys, it is expressed in the thick ascending limb (TAL) and the distal tubule (DT). In the TAL, activation of CaSR inhibits magnesium and calcium resorption by direct or indirect mechanisms. It also inhibits recycling of potassium back into the lumen by potassium channels. Peritoneal dialysis (PD) is thought to preserve the residual renal function (RRF) longer than hemodialysis. RRF is thus an important prognostic factor for PD patients. We investigated the effects on electrolyte balance and safety of cinacalcet. Six PD patients with RRF received once-daily oral cinacalcet at 25mg for two months. We examined the changes in levels of serum iPTH, and serum and urinary excretion of phosphorus, calcium, magnesium, and potassium for two months. Median (interquatile range: IQR) serum iPTH levels decreased significantly from 427.2 (351.2~1,313.3) pg/mL to 234.4 (86.0~721.3) pg/mL. Serum phosphorus levels and urinary excretion of phosphorus also decreased significantly. In contrast, concentrations of serum calcium, magnesium, and potassium, and urinary excretion of calcium, magnesium, and potassium did not change significantly. Serum levels of magnesium and potassium were not significantly altered, and were within the normal ranges (before, median 2.2 (IQR: 1.9~2.3) mg/dL, after, median 2.0 (IQR: 1.8~2.5) mg/dL for Mg; and before, median 4.5 (IQR: 4.4~5.2) mEq/L to 4.6 (IQR: 4.2~4.8) mEq/L for K). Based on these findings regarding the potassium and magnesium balance, cinacalcet appears to be useful and safe for the treatment of secondary hyperparathyroidism in PD patients with RRF.

Journal

References(36)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top